Is a polypill beneficial in patients at intermediate CV risk? Probably not.
Bottom line: A polypill containing blood pressure-lowering therapy and a low-dose statin did decrease CV mortality and morbidity in this intermediate-risk population. Related studies that evaluated the benefit of rosuvastatin or blood pressure lowering found that only the rosuvastatin was beneficial, so most of the benefit found in the polypill is driven by the statin.
Evidence-based practice 20, no. 3 (2017): E8